Navigation Links
Angiotech and Symphony Medical Announce Licensing Agreement
Date:1/17/2008

ts or developments expressed or implied by such forward-looking statements. Such factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; technological changes that impact our existing products or our ability to develop and commercialize future products; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; dependence upon, and relationships with strategic alliance partners to develop and commercialize products and services based on our work; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the size of the market and the potential market for our products in specific disease areas, other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to successfully complete preclini
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
(Date:12/19/2014)... Arlington, MA (PRWEB) December 18, 2014 ... products for ophthalmology and wound care. The National Eye ... has awarded LayerBio a Phase I SBIR grant to ... , Cataracts are the most common cause of vision ... cause of blindness worldwide. According to Dr. Ken Mandell, ...
(Date:12/19/2014)... The empty capsules market is experiencing growth primarily ... innovations in the empty capsules market. The fast-growing ... of the empty capsules market. , Get Full ... Report , The report will enrich both established ... gauge the pulse of the market which in ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... TEL-AVIV, Israel, October 17 TopSpin Medical,(TASE: TOPMD), ... MRI,using an IntraVascular MRI (IVMRI) catheter for the ... Ph.D., as Vice President,Clinical Affairs. Dr. Setum ... research in,the medical device industry. She has a ...
... Oct. 17 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... that its lead product candidate, picoplatin,has been granted ... cell lung cancer (SCLC) by the European Commission. ... Committee for Orphan Medicinal,Products (COMP) of the European ...
... GenVault announced today that,the Henry C. Witelson Ocular ... purchased a Personal Archive biosample management system.,The laboratory ... will be a critical component of the Laboratory,s,research ... as uveal,melanoma and retinoblastoma and for developing new ...
Cached Biology Technology:TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs 2Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 2Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 3Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 4McGill University Purchases GenVault's Personal Archive System to Manage Rare Cancer Samples 2
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need ... your password, site key or the answer to your secret ... teacher? Today, Hoyos Labs , a ... will finally put an end to the frustration that comes ... . 1U leverages a user,s smartphone to acquire his or ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... Health announced today that it will fund 22 grants ... modifications to genes that result from diet, aging, stress, ... human diseases and biological processes. The awards ... of the NIH Roadmap for Medical Research,s Epigenomics Program. ...
... Prevention Institute at Kansas State University is being honored ... Prevention Roundtable. The K-State institute,s intern program has ... award, also called the MVP2 award, as the best ... Sept. 22, in Washington, D.C. The award is ...
... Calif., September 15, 2009 -- Researchers at the ... that reactive oxygen species, such as superoxide and ... invadopodia, cellular protrusions implicated in cancer cell migration ... director of the Tumor Microenvironment Program at Burnham,s ...
Cached Biology News:NIH funds grantees focusing on epigenomics of human health and disease 2NIH funds grantees focusing on epigenomics of human health and disease 3NIH funds grantees focusing on epigenomics of human health and disease 4K-State Pollution Prevention Institute's intern program named best 2Reactive oxygen's role in metastasis 2
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
... Plus is formulated for covering tissue sections and ... soluble OR alcohol insoluble end products. ... as Fast Red or AEC that require an ... such as DAB. No heating is required prior ...
Biology Products: